Patent application number | Description | Published |
20080305474 | Method and Apparatus for Using SLC2A10 Genetic Polymorphisms for Determining Peripheral Vascular Disease in Patients with Type-2 Diabetes - Recent data indicate that a loss-of-function mutation of the SLC2A10 gene causes arterial tortuosity syndrome (ATS) via upregulation of the TGF-β pathway in the arterial wall, a mechanism possibly causing vascular changes associated with diabetes. It is determined that SLC2A10 (Solute carrier family 2, facilitated glucose transporter, member 10) genetic polymorphism is associated with peripheral vascular disease (PVD) in patients with type 2 diabetes. | 12-11-2008 |
20110014215 | GRANULYSIN AND USES THEREOF - Disclosed are uses of granulysin in methods of diagnosing or treating autoimmune disorders. | 01-20-2011 |
20110212439 | HLA ALLELES ASSOCIATED WITH ADVERSE DRUG REACTIONS AND METHODS FOR DETECTING SUCH - This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601). | 09-01-2011 |
20110236885 | Genetic Variants Predicting Warfarin Sensitivity - We discovered that a polymorphism in the promoter of the VKORC1 gene is associated with warfarin sensitivity. This polymorphism can explain both the inter-individual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. Thus, the promoter sequence or activity of the VKORC1 gene of a subject can be used to predict how much warfarin should be prescribed for the subject. Relevant methods and compositions are provided. | 09-29-2011 |
20110251074 | METHOD FOR IDENTIFYING HLA COMPLEXES ASSOCIATED WITH ADVERSE DRUG REACTIONS - A method for identifying from an HLA library an HLA complex that specifically binds to a compound. This method can be relied on to assess whether a compound is likely to induce an adverse drug reaction and, if so, in which human population. | 10-13-2011 |
Patent application number | Description | Published |
20080227109 | Risk assessment for adverse drug reactions - The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB 1 and HLA-A region of the specific HLA-B haplotype can also be used for the test. | 09-18-2008 |
20090053727 | Risk Assessment For Adverse Drug Reactions - The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test. | 02-26-2009 |
20120077192 | Risk Assessment For Adverse Drug Reactions - The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test. | 03-29-2012 |
20130330724 | RISK ASSESSMENT FOR ADVERSE DRUG REACTIONS - The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test. | 12-12-2013 |
20150361498 | GENETIC VARIANTS ASSOCIATED WITH LITHIUM RESPONSE IN BIPOLAR DISORDER - Described herein is a method of determining lithium responsiveness in a bipolar disorder patient. The method includes obtaining a sample from a patient having bipolar disorder, and assaying the sample for the presence or absence of one or more glutamate decarboxylase-like 1 (GADL1) gene variants selected from the group consisting of a T allele of the single nucleotide polymorphism (SNP) rs17026688, a G allele of the SNP rs17026651, and GADL1 1VS8+48delG. The presence of one or more of the GADL1 gene variants indicates that the patient is responsive to lithium treatment. | 12-17-2015 |